UNSPSC 51332849: Fluphenazine dihydrochloride

This classification denotes an antipsychotic agent with the molecular formula C22H26F3N3OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZOU145W1XL, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- but more generally known as fluphenazine dihydrochloride, which bears US NIH Compound Identifier 3372. European Medicines Agency schedules Fluphenazine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02232MIG.

Most nations, for tariff and trade purposes, schedule fluphenazine dihydrochloride under HS 29343090. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)C(F)(F)F)CCCN4CCN(CC4)CCO.CL.CL.

UNSPSC 51332849 Fluphenazine dihydrochloride is a Commodity code nominally identifying a specific antipsychotic pharmaceutical, but recent state and local procurement activity under this code shows a substantial mismatch between the code's narrow product designation and what is actually being solicited. The opportunities posted under this code involve broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products — rather than fluphenazine specifically. State and local issuing bodies applying this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances administering pharmaceutical contracts on behalf of state and local governments and school districts. The work involves establishing supply relationships for pharmaceutical products through authorized wholesalers, negotiating pricing models with manufacturers, and managing quarterly or ongoing deliveries to health facilities and benefit programs.

Recent activity appears concentrated in Florida and Texas, with multistate coverage through cooperative purchasing vehicles like MMCAP (Minnesota Multistate Cooperative Purchasing Alliance), which serves participating states including Oregon. Representative opportunities include Seminole County's competitive bid (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building; Texas HHS's Request for Information (RFI HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription program capabilities; and MMCAP's Request for Proposal (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities nationwide. The code shows limited signal for fluphenazine-specific procurement and significant tagging inconsistency across state and local jurisdictions.